澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

RACE ONCOLOGY LTD

1.760

-0.055-3.03%

成交量：5.57万

成交额：10.01万

市值：3.45亿

市盈率：-28.43

高：1.845

开：1.815

低：1.760

收：1.815

52周最高：4.660

52周最低：1.760

股本：1.96亿

流通股本：1.21亿

量比：1.02

换手率：0.05%

股息：- -

股息率：- -

每股收益(TTM):-0.062

每股收益(LYR):-0.062

净资产收益率：-42.28%

总资产收益率：-23.40%

市净率：9.47

市盈率(LYR):-28.43

数据加载中...

总览公司新闻资讯公告

概念

医药生物股+0.66%

资金流向

资金流入：

资金流出：

新闻资讯

Racura Oncology获批在EGFR突变非小细胞肺癌一期Harness-1试验中将RC220剂量递增至100 Mg/M2

Racura Oncology通过配售与跟投及奖励期权资金，筹集3120万美元支持RC220临床开发

瑞库拉肿瘤学宣布CPACS临床试验获得安全审查委员会积极推荐

Racura Oncology 宣布Cpacs临床试验获安全审查委员会积极建议

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/RAC.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":1.76,"timestamp":1791781920000,"preClose":1.815,"halted":0,"volume":55732,"delay":0,"changeRate":-0.03030303030303027,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":196068940,"eps":-0.0619,"marketStatus":"未开盘","change":-0.055,"latestTime":"10-12 16:12:00 AEDT","open":1.815,"high":1.845,"low":1.76,"amount":100066,"amplitude":0.046832,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0619,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.815,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":1.023078560344909,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAC.AU","preClose":1.815,"auctionPrice":1.76,"auctionVolume":30,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781790273}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-23.40%","roe":"-42.28%","lyrEps":-0.0619,"volumeRatio":1.023078560344909,"shares":196068940,"dividePrice":0,"high":1.845,"amplitude":0.046832,"preClose":1.815,"low":1.76,"week52Low":1.76,"pbRate":"9.47","psRate":"122.76","week52High":4.66,"institutionHeld":0,"latestPrice":1.76,"eps":-0.0619,"divideRate":0,"volume":55732,"delay":0,"ttmEps":-0.0619,"open":1.815,"prevYearClose":2.73,"prevWeekClose":1.815,"prevMonthClose":1.89,"prevQuarterClose":1.89,"fiveDayClose":1.93,"twentyDayClose":2,"sixtyDayClose":2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1119919563","title":"Racura Oncology获批在EGFR突变非小细胞肺癌一期Harness-1试验中将RC220剂量递增至100 Mg/M2","url":"https://stock-news.laohu8.com/highlight/detail?id=1119919563","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119919563?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:01","pubTimestamp":1791802889,"startTime":"0","endTime":"0","summary":"Racura Oncology获批在EGFR突变非小细胞肺癌一期Harness-1试验中将RC220剂量递增至100 Mg/M2","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168425417","title":"Racura Oncology通过配售与跟投及奖励期权资金，筹集3120万美元支持RC220临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1168425417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168425417?lang=zh_cn&edition=fundamental","pubTime":"2026-06-04 06:53","pubTimestamp":1780527198,"startTime":"0","endTime":"0","summary":"Racura Oncology宣布，公司通过股权配售，并结合跟投与奖励期权计划所获资金，成功筹集了总计3120万美元。这笔资金将专项用于支持其候选药物RC220的临床开发项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149868178","title":"瑞库拉肿瘤学宣布CPACS临床试验获得安全审查委员会积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1149868178","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149868178?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 19:23","pubTimestamp":1778844180,"startTime":"0","endTime":"0","summary":"瑞库拉肿瘤学有限公司宣布，其正在进行的CPACS临床试验获得了安全审查委员会的积极推荐。\n瑞库拉肿瘤学有限公司指出，在第一队列中，单独使用RC220或与多柔比星联合使用均未发现安全性问题。\n瑞库拉肿瘤学有限公司表示，将在80毫克/平方米的RC220剂量水平上，启动第二队列患者的筛选工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108465491","title":"Racura Oncology 宣布Cpacs临床试验获安全审查委员会积极建议","url":"https://stock-news.laohu8.com/highlight/detail?id=1108465491","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108465491?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 19:08","pubTimestamp":1778843295,"startTime":"0","endTime":"0","summary":"Racura Oncology宣布，其正在进行的Cpacs临床试验已获得安全审查委员会的积极建议，标志着该研究的一个重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAC.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"医药生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.006583}]}}